XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
  Depression
   Antidepressants
  Neuropsychiatry
  Personality Disorders
  Bulimia
  Anxiety
  Substance Abuse
  Suicide
  CFS
  Psychoses
  Child Psychiatry
  Learning-Disabilities
  Psychology
  Forensic Psychiatry
  Mood Disorders
  Sleep Disorders
  Peri-Natal Psychiatry
  Psychotherapy
  Anorexia Nervosa
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

Depression Channel
subscribe to Depression newsletter

Latest Research : Psychiatry : Depression

   DISCUSS   |   EMAIL   |   PRINT
Link Between Depression and Heart Disease
Jul 4, 2006 - 1:43:00 AM, Reviewed by: Dr. Venkat Yelamanchili

"Those people with a history of depression who received a cortisol inhibitor showed an improvement in blood vessel function compared to the placebo group. Although this was a small-scale trial it does open up the possibility that suppressing cortisol in patients who have a history of depression could be a way of reducing their higher risk of developing heart disease."

 
Naturally occurring steroids in the body may make people with a history of depression more vulnerable to coronary heart disease, according to new research from the University of Birmingham.

The small-scale trial of Metyrapone, which inhibits the production of the steroid hormone cortisol, significantly improved the function of the blood vessel lining, known as 'endothelium', in people who had a history of depression. The results, which are published in the current edition of the Journal of the American College of Cardiology, suggest that cortisol may play a significant role in causing damage to the endothelium of people who have recurrent depression.

Professor Michael Frenneaux, British Heart Foundation Professor in Cardiology, who led the research, explains: "We already know that people with a history of depression are at greater risk of heart disease. Our previous work has also shown that these people have significant problems with the lining of their blood vessels, which increases their risk of vascular problems or coronary heart disease. These results suggest that cortisol plays a role in creating these problems, which increases the risk of heart disease."

66 people, half of whom had previously suffered from depression, were involved in the trial, taking either Metyrapone or a placebo. The trial looked to assess whether blocking cortisol could improve the function of the blood vessel lining. The research team measured each person's endothelial function before, and six hours after, receiving Metryapone, a drug which blocks the production of cortisol.

The results showed improvement in the function of the endothelium in those people who received Metyrapone compared to the control group.

Professor Frenneaux continues: "Those people with a history of depression who received a cortisol inhibitor showed an improvement in blood vessel function compared to the placebo group. Although this was a small-scale trial it does open up the possibility that suppressing cortisol in patients who have a history of depression could be a way of reducing their higher risk of developing heart disease."
ENDS
 

- Metyrapone Improves Endothelial Dysfunction in Patients With Treated Depression, is published in the Journal of the American College of Cardiology.
 

www.vip2.bham.ac.uk

 
Subscribe to Depression Newsletter
E-mail Address:

 

Metyrapone is a drug used in the diagnosis of adrenal insufficiency.

Related Depression News

New brain-chemistry differences found in depressed women
Stereotypical self-image interferes with depression treatment
Exaggerated inflammatory response to psychological stress seen in major depression
Ever-happy mice may hold key to new treatment of depression
Treating depression may raise anxiety levels
Depressed singles receive greater psychological benefits from getting married
STAR*D Trial: Third antidepressant medication might help in treatment-resistant depression
Residual Depressive Cognitions could Predict Relapse of Depressive Illness
Link Between Depression and Heart Disease
Social factors not hormones cause post-natal depression


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us